stocks logo

CRDL

Cardiol Therapeutics Inc
$
1.530
+0.09(6.250%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.590
Open
1.490
VWAP
--
Vol
927.19K
Mkt Cap
126.45M
Low
1.400
Amount
--
EV/EBITDA(TTM)
--
Total Shares
69.00M
EV
150.42M
EV/OCF(TTM)
--
P/S(TTM)
--
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Show More
2 Analyst Rating
up Image
455.56% Upside
Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image
455.56% Upside
Current: 1.530
sliders
Low
8.00
Averages
8.50
High
9.00
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$9
2025-06-02
Reason
H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-04-16
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-04-07
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-02-24
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2024-12-18
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2024-11-20
Reason

Valuation Metrics

The current forward P/E ratio for Cardiol Therapeutics Inc (CRDL.O) is -3.87, compared to its 5-year average forward P/E of -4.33. For a more detailed relative valuation and DCF analysis to assess Cardiol Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.33
Current PE
-3.87
Overvalued PE
-2.30
Undervalued PE
-6.36

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.83
Current EV/EBITDA
-5.49
Overvalued EV/EBITDA
-0.87
Undervalued EV/EBITDA
-6.79

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
26.03
Current PS
0.00
Overvalued PS
94.46
Undervalued PS
-42.40

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+0.28%
-8.43M
Operating Profit
FY2025Q1
YoY :
-9.72%
-8.29M
Net Income after Tax
FY2025Q1
YoY :
-28.57%
-0.10
EPS - Diluted
FY2025Q1
YoY :
+3.46%
-7.17M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CRDL News & Events

News

9.0
07-22NASDAQ.COM
Cardiol To Report ARCHER Study Data Within The Next Two Weeks
4.0
06-02Benzinga
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
4.0
06-02Benzinga
HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9
Sign Up For More News

FAQ

arrow icon

What is Cardiol Therapeutics Inc (CRDL) stock price today?

The current price of CRDL is 1.53 USD — it has increased 6.25 % in the last trading day.

arrow icon

What is Cardiol Therapeutics Inc (CRDL)'s business?

arrow icon

What is the price predicton of CRDL Stock?

arrow icon

What is Cardiol Therapeutics Inc (CRDL)'s revenue for the last quarter?

arrow icon

What is Cardiol Therapeutics Inc (CRDL)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Cardiol Therapeutics Inc (CRDL)'s fundamentals?

arrow icon

How many employees does Cardiol Therapeutics Inc (CRDL). have?

arrow icon

What is Cardiol Therapeutics Inc (CRDL) market cap?